Clinical Trial Update: Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial entry for JSKN016 as neoadjuvant therapy in resectable stage II-III non-small cell lung cancer; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JSKN016

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: NSCLC Stage II | Phase 2 | Status: NOT_YET_RECRUITING